Three newly approved drugs for chronic lymphocytic leukemia (CLL): Incorporating ibrutinib, idelalisib and obinutuzumab into clinical practice

Por Sanford, David, Wierda, William G., Burger, Jan A., Keating, Michael J., O’Brien, Susan M.
Publicado no Clin Lymphoma Myeloma Leuk (2015)

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Por O'Brien, Susan M., Claxton, David F., Crump, Michael, Faderl, Stefan, Kipps, Thomas, Keating, Michael J., Viallet, Jean, Cheson, Bruce D.
Publicado no Blood (2009)

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

Por Strati, Paolo, Keating, Michael J., Burger, Jan A., O’Brien, Susan M., Wierda, William G., Estrov, Zeev, Zacharian, Gracy, Ferrajoli, Alessandra
Publicado no Haematologica (2017)

Fludarabine, Cyclophosphamide, and Multiple-Dose Rituximab as Frontline Therapy for Chronic Lymphocytic Leukemia

Por Short, Nicholas J., Keating, Michael J., Wierda, William G., Faderl, Stefan, Ferrajoli, Alessandra, Estrov, Zeev, Smith, Susan C., O'Brien, Susan M.
Publicado no Cancer (2015)

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

Por Strati, Paolo, Keating, Michael J., O’Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan, Faderl, Stefan, Tambaro, Francesco Paolo, Jain, Nitin, Wierda, William G.
Publicado em 2014

Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity

Por Thompson, Philip A, Stingo, Francesco, Keating, Michael J, Ferrajoli, Alessandra, Burger, Jan A., Wierda, William G, Kadia, Tapan M, O’Brien, Susan M.
Publicado no Cancer (2016)

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

Por Cheson, Bruce D., Byrd, John C., Rai, Kanti R., Kay, Neil E., O'Brien, Susan M., Flinn, Ian W., Wiestner, Adrian, Kipps, Thomas J.
Publicado em 2012

Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Por Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Sargent, Rachel, Burger, Jan A., Ferrajoli, Alessandra
Publicado no J Clin Oncol (2013)

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

Por Chen, Qiushi, Jain, Nitin, Ayer, Turgay, Wierda, William G., Flowers, Christopher R., O’Brien, Susan M., Keating, Michael J., Kantarjian, Hagop M., Chhatwal, Jagpreet
Publicado no J Clin Oncol (2017)

β(2)-microglobulin Normalization Within 6 months of Ibrutinib-based Treatment is Associated with Superior PFS in CLL

Por Thompson, Philip A., O’Brien, Susan M., Xiao, Lianchun, Wang, Xuemei, Burger, Jan A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G.
Publicado no Cancer (2015)

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Por Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Publicado em 2011

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Por Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Publicado em 2011

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

Por Thompson, Philip A., Tam, Constantine S., O’Brien, Susan M., Wierda, William G., Stingo, Francesco, Plunkett, William, Smith, Susan C., Kantarjian, Hagop M., Freireich, Emil J., Keating, Michael J.
Publicado no Blood (2016)

Soluble syndecan-1 (sCD138) as a prognostic factor independent of IgVH mutation status in patients with chronic lymphocytic leukemia

Por Jilani, Iman, Wei, Caimiao, Bekele, B. Nebiyou, Zhang, Zhong J, Keating, Michael, Wierda, William, Ferrajoli, Alessandra, Estrov, Zeev, Kantarjian, Hagop, O'Brien, Susan M, Giles, Francis J, Albitar, Maher
Publicado em 2008

Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia

Por Wierda, William G., Kipps, Thomas J., Keating, Michael J., Brown, Jennifer R., Gribben, John G., Browning, Mary, Rassenti, Laura Z., Greaves, Andrew W., Neuberg, Donna, O’Brien, Susan M.
Publicado no Cancer (2010)

The Addition of CD20 Monoclonal Antibodies to Lenalidomide Improves Response Rates and Survival in Relapsed/refractory patients with CLL Relative to Lenalidomide Monotherapy – The...

Por Thompson, Philip A., Rosovski, Uri, Keating, Michael J., Stingo, Francesco, Smith, Susan C., Wierda, William G., Falchi, Lorenzo, O'Brien, Susan M., Estrov, Zeev, Burger, Jan A., Ferrajoli, Alessandra
Publicado no Br J Haematol (2015)

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Por Strati, Paolo, Keating, Michael J., O'Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G.
Publicado em 2014

Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens

Por Thompson, Philip A., O’Brien, Susan M., Wierda, William G., Ferrajoli, Alessandra, Stingo, Francesco, Smith, Susan C., Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kantarjian, Hagop M., Keating, Michael J.
Publicado no Cancer (2015)

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Por Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Lee, Bang-Ning, Sivina, Mariela, Reuben, James, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Kornblau, Steven M., Burger, Jan A., Ferrajoli, Alessandra
Publicado em 2011

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Por Short, Nicholas J., Jabbour, Elias, Sasaki, Koji, Patel, Keyur, O’Brien, Susan M., Cortes, Jorge E., Garris, Rebecca, Issa, Ghayas C., Garcia-Manero, Guillermo, Luthra, Rajyalakshmi, Thomas, Deborah, Kantarjian, Hagop, Ravandi, Farhad
Publicado no Blood (2016)